Pearls from: Hossein Borghaei, DO
(MedPage Today) -- Thoracic oncologist discusses turning the corner in SCLC therapies (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 29, 2016 Category: Primary Care Source Type: news
Yervoy Plus Chemo Disappoints in SCLC (CME/CE)
(MedPage Today) -- Combo treatment did not prolong survival versus chemo alone in extensive-stage disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2016 Category: Hematology Source Type: news
PharmaMar begins Phase III ATLANTIS trial of PM1183 combined with doxorubicin to treat SCLC
Spanish biopharmaceutical company PharmaMar has initiated the pivotal Phase III ATLANTIS study of PM1183 combined with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) to treat small-ce … (Source: Drug Development Technology)
Source: Drug Development Technology - August 2, 2016 Category: Pharmaceuticals Source Type: news
PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in SCLC
(Pharmamar) PharmaMar today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or the combination VCR in patients with small cell lung cancer after the failure of one prior platinum-containing line. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2016 Category: Cancer & Oncology Source Type: news
Two-drug immunotherapy deemed safe for lung cancer patients, Moffitt study shows
(H. Lee Moffitt Cancer Center & Research Institute) A new Moffitt Cancer Center study being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published in The Lancet Oncology shows that utilizing the immunotherapeutic agents nivolumab and ipilimumab could lead to more effective treatment options for SCLC patients who fail initial therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2016 Category: Cancer & Oncology Source Type: news
AbbVie to take over Stemcentrx and its Rova-T therapy for SCLC for $5.8bn
US-based biopharmaceutical company AbbVie will acquire biotechnology company Stemcentrx for nearly $5.8bn. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 2, 2016 Category: Pharmaceuticals Source Type: news
Second-line Therapy for SCLC: Potential Role of CTCsSecond-line Therapy for SCLC: Potential Role of CTCs
Do circulating tumor cells in recurrent SCLC have chemosensitivity? Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
G1 Therapeutics begins G1T28’s two Phase Ib / IIa trials for SCLC
Clinical-stage pharmaceutical firm G1 Therapeutics has commenced two Phase Ib / IIa trials of the CDK4 / 6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 11, 2015 Category: Pharmaceuticals Source Type: news
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
Dateline City:
KENILWORTH, N.J.
New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers
Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the first-time presentation of findings investigating
the use of KEYTRUDA® (pembrolizumab), the company’s ...
Source: Merck.com - Research and Development News - June 1, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
PharmaMar will start a Phase III study of PM1183 plus doxorubicin in relapsed SCLC
(Pharmamar) Data from a Phase 1b study demonstrate a marked anti-tumor activity in patients with relapsed SCLC treated with PM01183 in combination with doxorubicin, which was in general well-tolerated and induced several complete responses. PharmaMar will start a pivotal Phase 3 trial to compare PM01183 plus doxorubicin against topotecan in relapsed SCLC as second-line therapy, the only drug approved by the EMA and the FDA for this indication (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 13, 2015 Category: Biology Source Type: news
CytRx begins Phase IIb trial of aldoxorubicin to treat lung cancer
US-based biopharmaceutical research and development firm CytRx, has started a global Phase IIb clinical trial assessing aldoxorubicin compared to topotecan in patients with extensive-stage small cell lung cancer (SCLC,) who have relapsed or were refr… (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2014 Category: Pharmaceuticals Source Type: news
Consistent Genomic Alterations in SCLCConsistent Genomic Alterations in SCLC
Can high-sensitivity genomic profiling discover actionable genomic alterations and potential new routes to targeted therapies in patients with SCLC? Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 23, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Mixed Results With Thoracic RT in Advanced SCLC
SAN FRANCISCO (MedPage Today) -- Thoracic radiotherapy failed to improve 1-year survival in patients with advanced small cell lung cancer, but 2-year survival did improve significantly, a randomized trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2014 Category: Hematology Source Type: news
Oncology Experts Mark 20 Years of Evidence-Based Decision-Making in Small Cell Lung Cancer
NCCN has published the 20th annual edition of its NCCN Guidelines® for Small Cell Lung Cancer, marking the first 20th edition of the eight original NCCN Guidelines published in November 1996.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) has published its 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC). One of the eight original NCCN Guidelines®, the NCCN Guidelines for SCLC was initially ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - September 6, 2014 Category: Cancer & Oncology Source Type: news
Mixed Results in NSCLC, SCLC Trials (CME/CE)
(MedPage Today) -- Two-thirds of patients with recurrent, mutated non-small cell lung cancer responded to an investigational agent that selectively targets mutant cells and spares normal ones, results of a preliminary trial showed. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 2, 2014 Category: Geriatrics Source Type: news
